AmerisourceBergen Corporation(ABC) Stock Research - Grey Stern Research

AmerisourceBergen Corporation (ABC) Stock Analysis

$179.98 (-0.23%)

ABC Financial Performance


Use the table below to view AmerisourceBergen Corporation's financial profile. This data is gathers from the latest available financial statements. Annual data is taken from the trailing 12 months of statements. All numbers are reported in US Dollars and so any foreign currencies are converted to USD so comparison's can be done.

Based on Financial Statements from Q3 - 2024

Metric Value Ranking among Peers
Price $179.98 -
52 Week Low $136.07 -
52 Week High $194.79 -
Market Cap $36.1 Billion 2/8
Gross Margin 3% 7/8
Profit Margin 0% 5/8
EBITDA margin 1% 4/8
Q3 - 2024 Revenue $79.1 Billion 2/8
Q3 - 2024 Earnings $7.5 Million 5/8
Q3 - 2024 Free Cash Flow $0 Million 8/8
Trailing 4 Quarters Revenue $294.0 Billion 2/8
Trailing 4 Quarters Earnings $1.5 Billion 2/8
Quarterly Earnings Growth -98% 6/8
Annual Earnings Growth -15% 4/8
Quarterly Revenue Growth 15% 2/8
Annual Revenue Growth 9% 3/8
Cash On Hand $3.1 Billion 2/8
Short Term Debt $576.3 Million 3/8
Long Term Debt $3.8 Billion 3/8

AmerisourceBergen Corporation Financial Metrics


Financial metrics are a set of useful numbers that can give key performance indicators of a company. The various metrics can include information about profitability, growth, and debt load. When combined and use properly they can tell an analyst a compelling fact-based story of how the company is currently performing. To compare AmerisourceBergen Corporation's metrics versus it's peers make sure to run our peer analysis tool.

Valuation Metrics

Metric Value Ranking among Peers
PE 23.89 4/8
PS 0.12 7/8
PB 45.95 1/8
PC 11.54 4/8
Liabilities to Equity 84.29 1/8
ROA 0.02 5/8
ROE 1.92 1/8
Current Ratio 1.01 6/8
Quick Ratio 0.05 5/8
Long Term Debt to Equity 4.84 1/8
Debt to Equity 5.58 1/8
Burn Rate 10.84 2/8
Cash to Cap 0.09 3/8
CCR 8/8
EV to EBITDA 88.39 1/8
EV to Revenue 0.13 7/8

Company Details

AmerisourceBergen Corporation sources and distributes pharmaceutical products in the United States and internationally. Its Pharmaceutical Distribution segment distributes brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to various healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. It also provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; and packaging solutions to various institutional and retail healthcare providers. In addition, this segment distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; provides other services primarily to physicians who specialize in various disease states, primarily oncology, as well as to other healthcare providers, including hospitals and dialysis clinics; and offers data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers. The company's Other segment provides integrated manufacturer services, such as clinical trial support, product post-approval, and commercialization support; specialty transportation and logistics services for the biopharmaceutical industry; and sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in the companion animal and production animal markets, as well as demand-creating sales force services to manufacturers. AmerisourceBergen Corporation was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.

CEO: Mr. Steven Collis

Website: https://www.amerisourcebergen.com

Address: 1300 Morris Dr Chesterbrook, PENNSYLVANIA

Exchange: New York Stock Exchange

Industry: Medical Distribution

AmerisourceBergen Corporation Peer Analysis


A useful and more reliable way of seeing the health of a company is to compare it to other companies operating in the same sector. Below is our list of companies which we rank are the closest peers to AmerisourceBergen Corporation. If you feel that peers should be added or removed from this list please contact us. To run an in-depth peer analysis which compares many financial metrics click on the link below.

Stock Ticker Market Cap
Patterson Companies, Inc. PDCO $2.8 Billion
Henry Schein, Inc. HSIC $8.0 Billion
McKesson Corporation MCK $87.1 Billion
Cardinal Health, Inc. CAH $33.2 Billion
Owens & Minor, Inc. OMI $536.9 Million
EDAP TMS S.A. EDAP $80.0 Million
Zynex, Inc. ZYXI $72.8 Million
Run Peer Analysis
Income Statement
Balance Sheet
Cash Flow Statement
ABC Income Statements
Quarter Year Revenue Earnings
Q4 2024 $ 79.1 Billion $7.5 Million
Q3 2024 $ 74.2 Billion $483.5 Million
Q2 2024 $ 68.4 Billion $420.8 Million
Q1 2024 $ 72.3 Billion $601.5 Million
Q4 2023 $ 68.9 Billion $350.6 Million
Q3 2023 $ 66.9 Billion $479.6 Million
Q2 2023 $ 63.5 Billion $435.4 Million
Q1 2023 $ 62.8 Billion $479.7 Million

View All

ABC Balance Sheets
Quarter Year Cash & Equivalents Total Assets Total Debt Total Equity
Q4 2024 $3.1 Billion $67.1 Billion $4.4 Billion $786.7 Million
Q3 2024 $3.3 Billion $66.8 Billion $4.7 Billion $1.1 Billion
Q2 2024 $2.1 Billion $63.9 Billion $5.2 Billion $1.4 Billion
Q1 2024 $2.9 Billion $64.7 Billion $4.8 Billion $1.1 Billion
Q4 2023 $2.6 Billion $62.6 Billion $4.8 Billion $666.3 Million
Q3 2023 $1.4 Billion $61.2 Billion $5.0 Billion $922.0 Million
Q2 2023 $1.5 Billion $58.8 Billion $4.9 Billion $511.1 Million
Q1 2023 $1.7 Billion $57.9 Billion $5.6 Billion $73.6 Million

View All

ABC Cash Flow Statements
Quarter Year freeCashFlow capitalExpenditure netChangeInCash
Q3 2024 $2.4 Billion -$117.9 Million $1.2 Billion
Q2 2024 -$991.2 Million -$112.8 Million -$903.3 Million
Q1 2024 $810.9 Million -$74.2 Million $283.2 Million
Q4 2023 $169.9 Million $0 $169.9 Million
Q3 2023 $640.7 Million -$104.3 Million -$140.4 Million
Q2 2023 $526.7 Million -$102.9 Million -$224.0 Million
Q1 2023 $634.4 Million -$75.7 Million -$1.7 Billion
Q4 2022 $990.9 Million -$173.6 Million $291.5 Million

View All

Cookies

We use cookies to offer a better browsing experience. Cookies enhance site navigation, analyze site usage, and assist in our marketing efforts. By clicking Accept. you agree to the storing of cookies on your device. To refuse all non-required cookies, click on Decline.

Accept View Terms & Conditions